ARTICLE | Emerging Company Profile
Synthekine launches with $82M to create new cytokine signals
Modality-agnostic newco gives cytokines the GPCR treatment for cancer and autoimmunity
September 18, 2020 1:38 AM UTC
Synthekine is translating the structural biology work of Stanford synthetic cytokine pioneer K. Chris Garcia into a broad platform that could generate therapeutic cytokine signals never seen in nature.
The company, which launched Thursday with an $82 million series A round co-led by Canaan Partners, Samsara BioCapital and The Column Group, aims to submit INDs for its first two oncology programs in 2021. It is also developing therapies for autoimmunity...